bridge loan of MSEK 9 to be repaid in December. With short-term funding secured, Xintela can focus on its projects. The recruitment of patients in the venous leg ulcer study advances and an interim report from the osteoarthritis study is expected by the end of Q1 2025. In parallel, the company is setting up the GMP process with Region Östergötland. This is Xintela's first
commercial agreement as a provider of advanced therapy medical products (ATMPs). Investors are also awaiting updates on the process with EQGen Biomedicals regarding EQSTEM.
Aktuellt
SENASTE
